Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab
Abstract Type I interferons contribute to the pathogenesis of several autoimmune disorders, including systemic lupus erythematosus (SLE), systemic sclerosis, cutaneous lupus erythematosus, and myositis. Anifrolumab is a monoclonal antibody that binds to subunit 1 of the type I interferon receptor (I...
Saved in:
Main Authors: | Pradeep Sharma, David W. Boulton, Lynn N. Bertagnolli, Weifeng Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13245 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recalcitrant Dermatomyositis Treated With Anifrolumab
by: Shivang Chaudhary, et al.
Published: (2025-01-01) -
Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab
by: Zahir Amoura, et al.
Published: (2025-01-01) -
Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
by: Wei Lu, et al.
Published: (2024-12-01) -
Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus
by: Bishoy Abdelmalik, BS, et al.
Published: (2025-01-01) -
A physiologically-based pharmacokinetic model for the antibiotic ertapenem
by: Michele L. Joyner, et al.
Published: (2015-09-01)